ALIVER Project overview Development of DIALIVE, a novel Liver Dialysis Device for the treatment of patients with Acute on Chronic Liver Failure (ACLF)



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 733057

Albumin Gambro Septex – Albumin 2 Removal (Allocated "FILTER SET 1") Gambro oXiris- Bacterial Endotoxin Removal (Allocated "FILTER SET 2") Heparin Syringe pump Blood pump 1 Bubble trap **Pre-Diluter Solution bag** Effluent bag Dialysate bag Safety valve 6 Pump Pressure sensor 11. Sampling site 8 7 6 Extracorporeal Regulatory Status Support Equipment **Prismaflex Monitor** CE 0086 च्चि **Extension Tubing** CE 0086 9 10 11 12 Accessories CE 0086

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

12.

12-Adsorbent Cluster for Albumin Dialysis-CE Marked



NEW Albumin ReCycler for Albumin Dialysis/Plasmapheresis -will be CE marked at Phase II Study



NEW Albumin ReCycler for Albumin Dialysis/Plasmapheresis -will be CE marked at Phase II Study – can be adapted to Albumin Volume



Set up of the ALIVER system

NATHAN DAVIES

UCL



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 733057

Components of the system

- The treatment system requires
- A Prismaflex monitor
- 1 septeX treatment kit
- 1 oXiris treatment kit
- 1 connecting tubing




Where we started




To treat the patient


The operator of the system should be trained and familiar with the Prismaflex system.

Set up involves the use of the two treatment kits placed in series.





The practicalities of the system



Set-up of the system

1. Load the septeX filter on the front of the machine using the automated system, then select the HF1000 protocol



Attach the second filter

2. Attach the oXiris filter using the black support on the RHS of the system



Connect the filter sets

3. Connect the septeX and oXiris filters using the custom tubing set








Completing the tubing set up

Attach the venous return line to the oXiris filter, and ensure bubble trap, pressure sensor and clamps are all in place.



Prime the system as normal





Additional priming

Add 1litre of saline using the manual priming function to ensure both filters are full.

Clamp off all of the dialysis and waste lines of the second filter, secure the second filter with a cable tie





System is now ready to run.

Advantages

The set-up and priming does not take longer than standard prismaflex protocols

All of the warning messages and alarms still function as normal


All of the clamps and safety systems still function as normal

Any staff with previous experience of running the prismaflex system will be able to monitor the patient for the duration of therapy

Schematic representation of a prototype of the Dialive LDD system

- Gambro Septex Albumin Removal (Allocated "FILTER SET 1")
- 2. Gambro oXiris– Bacterial Endotoxin Removal (Allocated "FILTER SET 2")
- 3. Heparin Syringe pump
- 4. Blood pump
- 5. Bubble trap
- 6. Pre-Diluter Solution bag
- 7. Effluent bag
- 8. Dialysate bag
- 9. Safety valve
- 10. Pump
- 11. Pressure sensor
- 12. Sampling site

Extracorporeal	Regulatory
Support Equipment	Status
Prismaflex Monitor	CE 0086
Extension Tubing	CE 0086
Accessories	CE 0086





Important aspects of the DIALIVE LDD treatment

- Patients randomised to receive DIALIVE treatment will be treated in a high dependency setting (HDU), Intensive Care Unit (ICU) or Transplant unit.
- <u>Vascular access</u> will be obtained via a jugular or femoral vein using a double lumen catheter. Insertion of catheter will be undertaken under aseptic conditions in accordance with local clinical practices. Correction of clotting according to local clinical practice.

The treatment will be delivered by the local site team, with the initial set-up and on-going support to be provided by the DIALIVE team.

Anticoagulation of the device as per local protocol for CRRT

- <u>Albumin replacement</u>, ideally at the end of the treatment cycle, of the estimated loss of 25-30 mg after 12 h treatment., by infusing 200 mls of 20% HAS (local brand) over 2 hrs. Episode (s) of haemodynamic instability such as hypotension should preferably be treated by one or more non-albumin fluid solutions of your choice in the first instance.
- Routine monitoring of the patients during treatment cycles will be undertaken as per standard haemofiltration parameters.